MULROY DENNIS 4

What Happened

Dennis Mulroy, Chief Financial Officer of Arcturus Therapeutics Holdings (ARCT), was granted an award of options to purchase 100,000 shares on May 1, 2026. The Form 4 reports the transaction as an award/grant (derivative) with a reported price of $0.00 — this reflects an option grant rather than a cash purchase or sale. No immediate cash value or exercised shares were reported in the filing.

Key Details

• Transaction date: May 1, 2026; Form 4 filed: May 7, 2026 (appears to be later than the typical two-business-day filing window).
• Transaction type: Award/Grant of options (derivative); 100,000 option shares reported.
• Reported price: $0.00 on the Form 4 (typical for option grants reported as awards).
• Vesting (from footnotes): Options granted under the Amended and Restated 2019 Omnibus Equity Incentive Plan. 25% vests on May 1, 2027 (one-year cliff); the remaining 75% vests in equal monthly increments over the following 36 months.
• Shares owned after transaction: Not specified in the summary provided — see the full Form 4 for total beneficial ownership details.
• No indication in the filing that options were exercised or shares sold; this is a compensation grant, not a market purchase or sale.

Context

• This is a compensation-related option grant (derivative award), which is common for executives and does not represent an immediate cash outlay or sale. Such grants are intended to align executive incentives with shareholder value over the vesting period.
• Because the filing date is several days after the transaction, readers may want to check the full Form 4 on the SEC site for any additional disclosures or explanations about timing.